IMTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Immatics N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$12.58 |
52 Week High | US$13.77 |
52 Week Low | US$7.15 |
Beta | 0.73 |
1 Month Change | 14.78% |
3 Month Change | 4.40% |
1 Year Change | -0.87% |
3 Year Change | 8.45% |
5 Year Change | 25.67% |
Change since IPO | 31.04% |
Recent News & Updates
Recent updates
Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now
May 03We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Sep 26We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Jun 12Immatics launches $110M stock offering
Oct 10Cancer immunotherapy biotech Immatics up 18% on 4x normal volume
Jul 19Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation
Jan 29Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher
Dec 16Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Apr 01What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?
Jan 18Immatics reports Q3 results
Dec 02Immatics (IMTX) Investor Presentation - Slideshow
Nov 13Shareholder Returns
IMTX | US Biotechs | US Market | |
---|---|---|---|
7D | -5.1% | -1.8% | 1.6% |
1Y | -0.9% | 5.5% | 22.3% |
Return vs Industry: IMTX underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: IMTX underperformed the US Market which returned 22.3% over the past year.
Price Volatility
IMTX volatility | |
---|---|
IMTX Average Weekly Movement | 8.7% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IMTX has not had significant price volatility in the past 3 months.
Volatility Over Time: IMTX's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 484 | Harpreet Singh | www.immatics.com |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
Immatics N.V. Fundamentals Summary
IMTX fundamental statistics | |
---|---|
Market cap | US$1.34b |
Earnings (TTM) | -US$86.22m |
Revenue (TTM) | US$79.96m |
16.2x
P/S Ratio-15.0x
P/E RatioIs IMTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMTX income statement (TTM) | |
---|---|
Revenue | €74.47m |
Cost of Revenue | €123.19m |
Gross Profit | -€48.72m |
Other Expenses | €31.58m |
Earnings | -€80.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.78 |
Gross Margin | -65.42% |
Net Profit Margin | -107.83% |
Debt/Equity Ratio | 0% |
How did IMTX perform over the long term?
See historical performance and comparison